title: International Congenital Cytomegalovirus Recommendations Group
text: |
  International Congenital Cytomegalovirus Recommendations Group
  |
  bet | 236/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  International Congenital Cytomegalovirus Recommendations Group: Ganciclovir is now available as an oral prodrug, valganciclovir. A recent RCT now recommends valganciclovir treatment for congenitally-infected neonates ≥ 32 weeks of life, with moderate to severe symptomatic disease, to be commenced within the first month of life and for 6 months. Antiviral therapy should not be administered to neonates with asymptomatic congenital cytomegalovirus infections. Antiviral therapy is not routinely recommended for asymptomatic congenital cytomegalovirus infection with isolated sensorineural hearing loss or for neonates with mildly symptomatic congenital cytomegalovirus infection.3
  |
  | |